Drug news
Cobicistat (Gilead Sciences) "booster" for AIDS drugs is filed at EMA
The marketing authorisation application (MAA) for the HIV drug "boosting" agent cobicistat from Gilead Sciences had been validated by the European Medicines Agency (EMA). cobicistat is a pharmaco-enhancing agent that increases blood levels of certain commercially available protease inhibitors, including atazanavir (Bristol-Myers Squibb's Reyataz) and darunavir (Janssen's Prezista), to enable once-daily dosing.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.